About MAX BioPharma

MAX BioPharma is a California-based, privately held, preclinical stage biopharmaceutical company developing lipid-based drug candidates, so-called oxysterols, for improved treatment options in debilitating and fatal human diseases. We are pioneering this new field using our platform technology, Oxysterol Therapeutics®, because we consider it a gateway to new treatments in numerous indications. Historically, while at UCLA, we discovered certain naturally occurring oxysterols with osteogenic (bone forming) properties. These natural compounds target specialized stem cells, called mesenchymal stem cells, and stimulate the formation of new bone by safely activating a specific cellular signaling pathway called Hedgehog signaling. Today, the company is translating this technology into the next generation of therapeutic agents for stimulation of bone formation for spine fusion, an orthopedic procedure that addresses spinal deformities. MAX BioPharma is also pursuing the development of oxysterol drug candidates that inhibit fibrotic diseases, for example non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), and chronic inflammatory diseases, for example atherosclerosis, obesity- and aging-associated inflammation, cystic fibrosis, and psoriatic arthritis. The company has also identified oxysterols that can block viral infections, such as hepatitis B, hepatitis C, and SARS-CoV-2 infections, and may have anti-viral activity in the context of HIV and other viral infections.